{"success":true,"data":{"pressRelease":{"id":"165007","rtpr_id":"nPNAY2hvZa-20261009","ticker":"1952","exchange":"HKEX","all_tickers":["1952"],"title":"Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development","author":"PR Newswire","published_at":"2026-10-09T02:16:19.410Z","article_body":"Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to\nAdvance Global Clinical Development\nPR Newswire\n\nSHANGHAI, Oct. 9, 2026\n* Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology\nTranslational Medicine at Moderna, and Brandon Coder, PhD, former Research &\nEarly Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines\n* Appointments support continued advancement of Everest's mRNA pipeline,\nincluding a planned Phase 1b investigator-initiated trial of EVM16 in Q4 2026,\nU.S. IND submission in early 2027, and EVM14 Phase 1 study completion in Q1\n2027\nSHANGHAI, Oct. 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK,\n\"Everest\", or the \"Company\"), a biopharmaceutical company focused on the\ndiscovery, clinical development, manufacturing, and commercialization of\ninnovative therapeutics, today announced the appointments of Lakshmi\nSrinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and\nBrandon Coder, PhD, as Vice President, Translational Sciences & Discovery. The\nappointments further strengthen the Company's global R&D capabilities in mRNA\ntherapeutics, and support the continued advancement of its proprietary mRNA\nplatform and pipeline. The Company will continue to invest in world-class\ntalent to accelerate the development of its mRNA programs and to realize the\nplatform's potential for global innovation.\n\nBoth executives are seasoned scientists in mRNA cancer vaccines, with deep\nexperience spanning early discovery through clinical development and\nleadership roles in oncology vaccine research at Moderna and other leading\nbiopharmaceutical companies. At Everest, they will drive clinical development\nof the Company's mRNA programs and expand Everest's presence in the United\nStates, in line with the Company's global mRNA R&D strategy, while working\nclosely with the China R&D team.\n\n\"We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest as we\ncontinue to strengthen our global mRNA R&D capabilities,\" said Mr. Yifang Wu,\nChairman of the Board of Everest Medicines. \"Their deep experience in cancer\nvaccine research, translational medicine, and clinical development will be\nhighly valuable as we advance our proprietary mRNA platform and broader\npipeline. Their appointments reflect our continued commitment to investing in\nworld-class talent and advancing our global mRNA strategy.\"\n\nLakshmi Srinivasan, PhD\n\nDr. Srinivasan is a seasoned immunologist with 20 years of experience\nadvancing innovative immuno-oncology therapeutics from discovery through\nclinical development. Her expertise spans cancer vaccines, mRNA-LNP\ntechnologies, T-cell therapies, and translational development from preclinical\nresearch through clinical proof of concept.\n\nPrior to joining Everest Medicines, Dr. Srinivasan served as Executive\nDirector and Head of Oncology Translational Medicine at Moderna Therapeutics\nfrom 2023 to 2025. She previously held leadership roles at Repertoire Immune\nMedicines, Neon Therapeutics (later acquired by BioNTech), and Sanofi\nOncology.\n\nDr. Srinivasan has played a key role in the clinical translation of\npersonalized neoantigen vaccines and has authored multiple high-profile\npublications in the field. She served as corresponding author on Phase 1b\nstudies of NEO-PV-01 published in Cell\n(https://pubmed.ncbi.nlm.nih.gov/33064988/) (2020)([1]) and Cancer Cell\n(https://pubmed.ncbi.nlm.nih.gov/36027916/) (2022),([2] )and co-authored\npublications on Moderna's intismeran autogene (mRNA-4157/V940), including the\nPhase 1 KEYNOTE-603 study published in Cancer Discovery\n(https://pubmed.ncbi.nlm.nih.gov/39115419/) (2024)([3])  and the three-year\nfollow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO\nOncology Advances\n(https://ascopubs.org/doi/10.1200/OA-25-00008?utm_source=chatgpt.com&referrer=https%3A%2F%2Fchatgpt.com%2F)\n(2026).([4]) \n\nDr. Srinivasan conducted postdoctoral research at the Immune Disease Institute\nat Harvard Medical School. She holds a PhD in Microbiology and Cell Biology\nfrom the Indian Institute of Science, a master's degree in biotechnology from\nJawaharlal Nehru University, and a bachelor's degree in biochemistry from\nDelhi University.\n\nBrandon Coder, PhD\n\nDr. Coder brings more than 11 years of industry experience advancing T cell\nimmunotherapies from discovery through investigational new drug (IND)\nsubmissions and early clinical proof of concept, with expertise in cancer\nvaccines, mRNA/LNP platform technology, and in vivo CAR therapies.\n\nPrior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna\nfrom 2019 to 2025, most recently as Associate Scientific Director of Cancer\nVaccine Research. He served as research and global pharmacology lead for\nintismeran autogene (mRNA-4157/V940), where he co-authored the Phase 1\nKEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery\n(https://pubmed.ncbi.nlm.nih.gov/39115419/) (2024).([3])  He also\nco-invented and led development of the shared-antigen discovery and vaccine\ndesign framework for mRNA-4359 and mRNA-4106.\n\nPreviously, Dr. Coder served as Associate Director of Immuno-Oncology Research\nat Advaxis Immunotherapies, where he developed personalized and off-the-shelf\ncancer vaccines. He holds a PhD in Biomedical Sciences, with a focus on\nimmunology and genetics, from the University of North Texas Health Science\nCenter and a bachelor's degree in biology from Texas Tech University.\n\nAbout Everest's mRNAPlatform\n\nEverest has built an industry-leading and fully integrated AI+mRNA platform\nthat accelerates mRNA product development.\n\nAs one of the few global biopharmaceutical companies with a fully integrated\nand proprietary mRNA platform, Everest has built end-to-end capabilities\nacross the entire value chain, covering antigen design, sequence optimization,\nLNP delivery, and scalable manufacturing. Everest has established and\noptimized its proprietary LNP delivery system, with patent coverage including\nionizable lipids and stealth lipids. The internal lipid library (>600 lipids)\nsupports multiple programs, including vaccines and in vivo CAR-T therapies.\nBacked by third-generation AI algorithms, Everest's AI+mRNA platform\nsignificantly boosts expression and immunogenicity, laying a solid foundation\nfor mRNA-based cancer vaccine development.\n\nLeveraging its proprietary AI+mRNA platform, Everest is advancing multiple\nmRNA therapeutic vaccine and in vivo CAR-T programs across oncology and\nautoimmune diseases.\n* EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its\nfirst-in-human clinical data readout, demonstrating a favorable safety and\ntolerability profile, robust immunogenicity, and promising preliminary\nefficacy. Selected data were presented at the 2026 American Association for\nCancer Research (AACR) Annual Meeting. Following the Phase 1a study, a Phase\n1b investigator-initiated trial (IIT) of EVM16 is planned in Q4 2026, with new\nindication expansion cohorts expected to further explore efficacy. The Company\nplans to submit an IND application to the U.S. Food and Drug Administration\n(FDA) in the first half of 2027.\n* EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine,\nreceived IND clearance from the U.S. FDA and IND approval from China's\nNational Medical Products Administration (NMPA) in 2025. The Phase 1\nmonotherapy dose-escalation study is expected to be completed in Q1 2027.\n* EVM18, an in vivo CAR-T therapy, is being evaluated in an IIT in autoimmune\ndiseases, with global IND filing underway.\nReference\n1. Ott PA, et al., A Phase Ib Trial of Personalized Neoantigen Therapy Plus\nAnti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or\nBladder Cancer. Cell, 2020\n2. Awad MA, et al., Personalized neoantigen vaccine NEO-PV-01 with\nchemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small\ncell lung cancer. Cancer Cell, 2022\n3. Gainor et al., T-cell Responses to Individualized Neoantigen Therapy\nmRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1\nKEYNOTE-603 Study. Cancer Discovery, 2024\n4. Carlino et al., Three-Year Update of a Randomized Phase IIb Study of the\nIndividualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus\nPembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO Oncology\nadvances, 2026\nAbout Everest Medicines\n\nEverest Medicines is a biopharmaceutical company focused on discovering,\ndeveloping, manufacturing and commercializing innovative pharmaceutical\nproducts that address critical unmet medical needs for patients in global\nmarkets. The management team of Everest Medicines has deep expertise and an\nextensive track record both in China and with leading global pharmaceutical\ncompanies.\n\nThe Company's therapeutic areas of focus include autoimmune, ophthalmology,\ncritical care, and CKM (cardiovascular, kidney, and metabolic) diseases.\nEverest Medicines has developed a fully integrated commercialization platform\nthat combines omnichannel commercial capabilities with end-to-end product\nlifecycle management. Leveraging its proprietary mRNA platform, the Company is\nadvancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer\nvaccines, while selectively expanding into additional high-value therapeutic\nareas with blockbuster potential, and accelerating its global expansion. For\nmore information, please visit the Company's website:\nwww.everestmedicines.com.\n\nForward-Looking Statements\n\nThis news release may make statements that constitute forward-looking\nstatements, including descriptions regarding the intent, belief or current\nexpectations of the Company or its officers with respect to the business\noperations and financial condition of the Company, which can be identified by\nterminology such as \"will,\" \"expects,\" \"anticipates,\" \"future,\" \"intends,\"\n\"plans,\" \"believes,\" \"estimates,\"\"confident\" and similar statements. Such\nforward-looking statements are not guarantees of future performance and\ninvolve risks and uncertainties, or other factors, some of which are beyond\nthe control of the Company and are unforeseeable. Therefore, the actual\nresults may differ from those in the forward-looking statements as a result of\nvarious factors and assumptions, such as future changes and developments in\nour business, competitive environment, political, economic, legal and social\nconditions. The Company or any of its affiliates, directors, officers,\nadvisors or representatives has no obligation and does not undertake to revise\nforward-looking statements to reflect new information, future events or\ncircumstances after the date of this news release, except as required by law.\n\nView original\ncontent:https://www.prnewswire.com/apac/news-releases/everest-medicines-appoints-two-veteran-mrna-cancer-vaccine-scientists-to-advance-global-clinical-development-302903189.html\n\nSOURCE Everest Medicines\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPNAY2hvZa-20261009","title":"Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development","author":"PR Newswire","ticker":"1952","created":"2026-10-09T02:16:19.410Z","tickers":["1952"],"exchange":"HKEX","article_body":"Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to\nAdvance Global Clinical Development\nPR Newswire\n\nSHANGHAI, Oct. 9, 2026\n* Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology\nTranslational Medicine at Moderna, and Brandon Coder, PhD, former Research &\nEarly Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines\n* Appointments support continued advancement of Everest's mRNA pipeline,\nincluding a planned Phase 1b investigator-initiated trial of EVM16 in Q4 2026,\nU.S. IND submission in early 2027, and EVM14 Phase 1 study completion in Q1\n2027\nSHANGHAI, Oct. 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK,\n\"Everest\", or the \"Company\"), a biopharmaceutical company focused on the\ndiscovery, clinical development, manufacturing, and commercialization of\ninnovative therapeutics, today announced the appointments of Lakshmi\nSrinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and\nBrandon Coder, PhD, as Vice President, Translational Sciences & Discovery. The\nappointments further strengthen the Company's global R&D capabilities in mRNA\ntherapeutics, and support the continued advancement of its proprietary mRNA\nplatform and pipeline. The Company will continue to invest in world-class\ntalent to accelerate the development of its mRNA programs and to realize the\nplatform's potential for global innovation.\n\nBoth executives are seasoned scientists in mRNA cancer vaccines, with deep\nexperience spanning early discovery through clinical development and\nleadership roles in oncology vaccine research at Moderna and other leading\nbiopharmaceutical companies. At Everest, they will drive clinical development\nof the Company's mRNA programs and expand Everest's presence in the United\nStates, in line with the Company's global mRNA R&D strategy, while working\nclosely with the China R&D team.\n\n\"We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest as we\ncontinue to strengthen our global mRNA R&D capabilities,\" said Mr. Yifang Wu,\nChairman of the Board of Everest Medicines. \"Their deep experience in cancer\nvaccine research, translational medicine, and clinical development will be\nhighly valuable as we advance our proprietary mRNA platform and broader\npipeline. Their appointments reflect our continued commitment to investing in\nworld-class talent and advancing our global mRNA strategy.\"\n\nLakshmi Srinivasan, PhD\n\nDr. Srinivasan is a seasoned immunologist with 20 years of experience\nadvancing innovative immuno-oncology therapeutics from discovery through\nclinical development. Her expertise spans cancer vaccines, mRNA-LNP\ntechnologies, T-cell therapies, and translational development from preclinical\nresearch through clinical proof of concept.\n\nPrior to joining Everest Medicines, Dr. Srinivasan served as Executive\nDirector and Head of Oncology Translational Medicine at Moderna Therapeutics\nfrom 2023 to 2025. She previously held leadership roles at Repertoire Immune\nMedicines, Neon Therapeutics (later acquired by BioNTech), and Sanofi\nOncology.\n\nDr. Srinivasan has played a key role in the clinical translation of\npersonalized neoantigen vaccines and has authored multiple high-profile\npublications in the field. She served as corresponding author on Phase 1b\nstudies of NEO-PV-01 published in Cell\n(https://pubmed.ncbi.nlm.nih.gov/33064988/) (2020)([1]) and Cancer Cell\n(https://pubmed.ncbi.nlm.nih.gov/36027916/) (2022),([2] )and co-authored\npublications on Moderna's intismeran autogene (mRNA-4157/V940), including the\nPhase 1 KEYNOTE-603 study published in Cancer Discovery\n(https://pubmed.ncbi.nlm.nih.gov/39115419/) (2024)([3])  and the three-year\nfollow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO\nOncology Advances\n(https://ascopubs.org/doi/10.1200/OA-25-00008?utm_source=chatgpt.com&referrer=https%3A%2F%2Fchatgpt.com%2F)\n(2026).([4]) \n\nDr. Srinivasan conducted postdoctoral research at the Immune Disease Institute\nat Harvard Medical School. She holds a PhD in Microbiology and Cell Biology\nfrom the Indian Institute of Science, a master's degree in biotechnology from\nJawaharlal Nehru University, and a bachelor's degree in biochemistry from\nDelhi University.\n\nBrandon Coder, PhD\n\nDr. Coder brings more than 11 years of industry experience advancing T cell\nimmunotherapies from discovery through investigational new drug (IND)\nsubmissions and early clinical proof of concept, with expertise in cancer\nvaccines, mRNA/LNP platform technology, and in vivo CAR therapies.\n\nPrior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna\nfrom 2019 to 2025, most recently as Associate Scientific Director of Cancer\nVaccine Research. He served as research and global pharmacology lead for\nintismeran autogene (mRNA-4157/V940), where he co-authored the Phase 1\nKEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery\n(https://pubmed.ncbi.nlm.nih.gov/39115419/) (2024).([3])  He also\nco-invented and led development of the shared-antigen discovery and vaccine\ndesign framework for mRNA-4359 and mRNA-4106.\n\nPreviously, Dr. Coder served as Associate Director of Immuno-Oncology Research\nat Advaxis Immunotherapies, where he developed personalized and off-the-shelf\ncancer vaccines. He holds a PhD in Biomedical Sciences, with a focus on\nimmunology and genetics, from the University of North Texas Health Science\nCenter and a bachelor's degree in biology from Texas Tech University.\n\nAbout Everest's mRNAPlatform\n\nEverest has built an industry-leading and fully integrated AI+mRNA platform\nthat accelerates mRNA product development.\n\nAs one of the few global biopharmaceutical companies with a fully integrated\nand proprietary mRNA platform, Everest has built end-to-end capabilities\nacross the entire value chain, covering antigen design, sequence optimization,\nLNP delivery, and scalable manufacturing. Everest has established and\noptimized its proprietary LNP delivery system, with patent coverage including\nionizable lipids and stealth lipids. The internal lipid library (>600 lipids)\nsupports multiple programs, including vaccines and in vivo CAR-T therapies.\nBacked by third-generation AI algorithms, Everest's AI+mRNA platform\nsignificantly boosts expression and immunogenicity, laying a solid foundation\nfor mRNA-based cancer vaccine development.\n\nLeveraging its proprietary AI+mRNA platform, Everest is advancing multiple\nmRNA therapeutic vaccine and in vivo CAR-T programs across oncology and\nautoimmune diseases.\n* EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its\nfirst-in-human clinical data readout, demonstrating a favorable safety and\ntolerability profile, robust immunogenicity, and promising preliminary\nefficacy. Selected data were presented at the 2026 American Association for\nCancer Research (AACR) Annual Meeting. Following the Phase 1a study, a Phase\n1b investigator-initiated trial (IIT) of EVM16 is planned in Q4 2026, with new\nindication expansion cohorts expected to further explore efficacy. The Company\nplans to submit an IND application to the U.S. Food and Drug Administration\n(FDA) in the first half of 2027.\n* EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine,\nreceived IND clearance from the U.S. FDA and IND approval from China's\nNational Medical Products Administration (NMPA) in 2025. The Phase 1\nmonotherapy dose-escalation study is expected to be completed in Q1 2027.\n* EVM18, an in vivo CAR-T therapy, is being evaluated in an IIT in autoimmune\ndiseases, with global IND filing underway.\nReference\n1. Ott PA, et al., A Phase Ib Trial of Personalized Neoantigen Therapy Plus\nAnti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or\nBladder Cancer. Cell, 2020\n2. Awad MA, et al., Personalized neoantigen vaccine NEO-PV-01 with\nchemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small\ncell lung cancer. Cancer Cell, 2022\n3. Gainor et al., T-cell Responses to Individualized Neoantigen Therapy\nmRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1\nKEYNOTE-603 Study. Cancer Discovery, 2024\n4. Carlino et al., Three-Year Update of a Randomized Phase IIb Study of the\nIndividualized Neoantigen Therapy Intismeran Autogene (mRNA-4157, V940) Plus\nPembrolizumab Versus Pembrolizumab in Resected Melanoma. JCO Oncology\nadvances, 2026\nAbout Everest Medicines\n\nEverest Medicines is a biopharmaceutical company focused on discovering,\ndeveloping, manufacturing and commercializing innovative pharmaceutical\nproducts that address critical unmet medical needs for patients in global\nmarkets. The management team of Everest Medicines has deep expertise and an\nextensive track record both in China and with leading global pharmaceutical\ncompanies.\n\nThe Company's therapeutic areas of focus include autoimmune, ophthalmology,\ncritical care, and CKM (cardiovascular, kidney, and metabolic) diseases.\nEverest Medicines has developed a fully integrated commercialization platform\nthat combines omnichannel commercial capabilities with end-to-end product\nlifecycle management. Leveraging its proprietary mRNA platform, the Company is\nadvancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer\nvaccines, while selectively expanding into additional high-value therapeutic\nareas with blockbuster potential, and accelerating its global expansion. For\nmore information, please visit the Company's website:\nwww.everestmedicines.com.\n\nForward-Looking Statements\n\nThis news release may make statements that constitute forward-looking\nstatements, including descriptions regarding the intent, belief or current\nexpectations of the Company or its officers with respect to the business\noperations and financial condition of the Company, which can be identified by\nterminology such as \"will,\" \"expects,\" \"anticipates,\" \"future,\" \"intends,\"\n\"plans,\" \"believes,\" \"estimates,\"\"confident\" and similar statements. Such\nforward-looking statements are not guarantees of future performance and\ninvolve risks and uncertainties, or other factors, some of which are beyond\nthe control of the Company and are unforeseeable. Therefore, the actual\nresults may differ from those in the forward-looking statements as a result of\nvarious factors and assumptions, such as future changes and developments in\nour business, competitive environment, political, economic, legal and social\nconditions. The Company or any of its affiliates, directors, officers,\nadvisors or representatives has no obligation and does not undertake to revise\nforward-looking statements to reflect new information, future events or\ncircumstances after the date of this news release, except as required by law.\n\nView original\ncontent:https://www.prnewswire.com/apac/news-releases/everest-medicines-appoints-two-veteran-mrna-cancer-vaccine-scientists-to-advance-global-clinical-development-302903189.html\n\nSOURCE Everest Medicines\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-09T02:16:19.466848849Z","server_sent_at_ms":1791512179466},"received_at":"2026-10-09T02:16:19.518Z","source_url":null},"analysis":{"id":"153407","press_release_id":"165007","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Everest Medicines appointed two veteran mRNA cancer-vaccine scientists from Moderna: Lakshmi Srinivasan as SVP, Head of Translational Medicine, and Brandon Coder as VP, Translational Sciences & Discovery.\n\nThe hires support the company's global mRNA R&D push, including a planned Phase 1b investigator-initiated trial of EVM16 in Q4 2026, a U.S. IND submission in early 2027, and EVM14 Phase 1 completion in Q1 2027.\n\nBoth executives bring direct experience from Moderna's personalized cancer vaccine program (mRNA-4157/V940), lending credibility to Everest's AI+mRNA platform and U.S. expansion strategy.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Moderna cancer-vaccine talent joins Everest as EVM16 and EVM14 hit key clinical milestones over the next two quarters."},"keyFigures":{"customDimensions":{"lipid_library_size":">600 lipids","evm16_us_ind_timing":"first half of 2027","evm14_phase1_completion":"Q1 2027","evm16_phase1b_iit_timing":"Q4 2026"}},"quotedText":"Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline.","namedEntities":{"people":[{"name":"Lakshmi Srinivasan","role":"Senior Vice President, Head of Translational Medicine (former Executive Director and Head of Oncology Translational Medicine at Moderna)"},{"name":"Brandon Coder","role":"Vice President, Translational Sciences & Discovery (former Research & Early Translational Lead, Cancer Vaccines at Moderna)"},{"name":"Yifang Wu","role":"Chairman of the Board"}],"products":["EVM16","EVM14","EVM18","intismeran autogene (mRNA-4157/V940)","NEO-PV-01","mRNA-4359","mRNA-4106"],"companies":[{"name":"Everest Medicines","ticker":"1952","relationship":"filer/issuer"},{"name":"Moderna Therapeutics","relationship":"prior employer of both hires"},{"name":"BioNTech","relationship":"acquired Neon Therapeutics, prior employer of Dr. Srinivasan"},{"name":"Sanofi","relationship":"prior employer of Dr. Srinivasan"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Two senior scientific hires (SVP/VP level, not C-suite) strengthen the mRNA R&D bench and support pipeline timelines (EVM16 Phase 1b in Q4 2026, U.S. IND in 2027, EVM14 Phase 1 completion Q1 2027). Positive but routine talent news with no financial figures."},"tickerRelevance":{"others":[],"primary":"1952"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap HK-listed biotech","eventGravity":"senior scientific hires, not C-suite","pipelineRelevance":"supports EVM16/EVM14 clinical timelines"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Everest Medicines appointed two veteran mRNA cancer-vaccine scientists from Moderna: Lakshmi Srinivasan as SVP, Head of Translational Medicine, and Brandon Coder as VP, Translational Sciences & Discovery.\n\nThe hires support the company's global mRNA R&D push, including a planned Phase 1b investigator-initiated trial of EVM16 in Q4 2026, a U.S. IND submission in early 2027, and EVM14 Phase 1 completion in Q1 2027.\n\nBoth executives bring direct experience from Moderna's personalized cancer vaccine program (mRNA-4157/V940), lending credibility to Everest's AI+mRNA platform and U.S. expansion strategy.","key_figures":{"customDimensions":{"lipid_library_size":">600 lipids","evm16_us_ind_timing":"first half of 2027","evm14_phase1_completion":"Q1 2027","evm16_phase1b_iit_timing":"Q4 2026"}},"named_entities":{"people":[{"name":"Lakshmi Srinivasan","role":"Senior Vice President, Head of Translational Medicine (former Executive Director and Head of Oncology Translational Medicine at Moderna)"},{"name":"Brandon Coder","role":"Vice President, Translational Sciences & Discovery (former Research & Early Translational Lead, Cancer Vaccines at Moderna)"},{"name":"Yifang Wu","role":"Chairman of the Board"}],"products":["EVM16","EVM14","EVM18","intismeran autogene (mRNA-4157/V940)","NEO-PV-01","mRNA-4359","mRNA-4106"],"companies":[{"name":"Everest Medicines","ticker":"1952","relationship":"filer/issuer"},{"name":"Moderna Therapeutics","relationship":"prior employer of both hires"},{"name":"BioNTech","relationship":"acquired Neon Therapeutics, prior employer of Dr. Srinivasan"},{"name":"Sanofi","relationship":"prior employer of Dr. Srinivasan"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-09T02:16:33.914Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"mid-cap HK-listed biotech","eventGravity":"senior scientific hires, not C-suite","pipelineRelevance":"supports EVM16/EVM14 clinical timelines"}},"durationMs":14382,"modelName":"glm-5.3-flashx"}}